ArticleJournal of inflammation research2025
Qingwen Hufei Granules Attenuate Lipopolysaccharide-Induced Acute Lung Injury by Suppressing NLRP3 Inflammasome-Dependent Pyroptosis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, clinical treatments for ALI include vasodilators, glucocorticoids, and mechanical ventilation; however, these therapies are associated with various adverse reactions. Therefore, there is a need to develop safer and more effective treatment options. Traditional Chinese Medicine (TCM), particularly Qingwen Hufei Granules (QHG), has demonstrated efficacy in treating respiratory disorders, including upper respiratory tract infections and influenza. However, the active components and mechanism of action of QHG remain unclear. Methods: Lipopolysaccharide (LPS) induced ALI mouse model. We analyzed the main pharmacodynamic components of QHG by HPLC, determined the effects of QHG on the cell viability and inflammatory factors of RAW264.7 cells, and recorded the body weight and lung tissue wet/dry (W/D) of ALI mice. Inflammatory factors in bronchoalveolar lavage fluid (BALF), serum, and lung tissue were determined using ELISA, and the protective effect of hematoxylin and eosin (H&E) staining of lung tissue was studied. Transcriptomic, qRT-PCR, Western blotting, immunohistochemistry, and immunofluorescence analyses were used to analyze QHG and explore the mechanism of ALI damage reduction. Results: The findings demonstrated that QHG effectively mitigated inflammatory cell invasion and pulmonary edema. Moreover, it diminished the concentrations of IL-6, TNF-α, and IL-1β in lung tissue, serum, and BALF. Furthermore, QHG notably decreased the levels of NO, reactive oxygen species(ROS), IL-6, IL-1β, and TNF-α in the supernatants of RAW264.7 cells. Transcriptomic analysis of the lung tissue revealed that QHG primarily enriched the NOD-like receptor (NLR) signaling pathway. qRT-PCR, Western blotting, immunohistochemistry, and immunofluorescence experiments confirmed that QHG mitigated ALI damage through the NLR signaling pathway. Furthermore, seven key components in QHG were determined by using HPLC. Conclusion: Our study demonstrated that QHG effectively mitigated LPS-induced ALI, and provided preliminary insights into its mechanism of action and material basis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.